Imuracetam
Imuracetam is an abandoned 1970s racetam development candidate from UCB Pharma (developmental code UCB-G218). | Compound
Aliases (2)
▸ Overview TL;DR
Imuracetam is an abandoned 1970s racetam development candidate from UCB Pharma (developmental code UCB-G218). It was never marketed, has no human trials in the published literature, no commercial form, no research-chem sourcing pipeline, and no community-anecdotal use base. It is functionally vaporware in the biohacker sense — name exists, compound does not. For actual racetam options, consult the family of marketed/research-chem compounds documented in the wiki: see the Cross-reference to actual racetam options section below.
▸ Pharmacokinetics No data
▸ What to expect Generic
- 1Week 1Tolerability and dose-response.
- 2Week 2-4Early effect window.
- 3Week 4-8Peak benefit assessment.
- 4Week 8+Cycle decision point.
▸References3 sources
Wikipedia — Imuracetam
confirms UCB-G218 developmental code, 1970s development, never marketed; stub-class article reflecting absence of literature
PubMed search for "imuracetam"
returns zero direct results; auto-redirects to dimiracetam (unrelated compound)
Medsafe NZ — Classification status of racetams
regulatory survey listing imuracetam alongside other racetams for completeness; no clinical data